Seattle Genetics stays step ahead of rivals with bladder cancer data

Seattle Genetics and Astellas on Friday said their bladder cancer drug Padcev kept patients with advanced-stage bladder cancer alive and in remission longer than did chemotherapy in a late-stage trial. The announcement came after an early data analysis, which found the drug improved survival.